 SAN DIEGO, CA ACCESSWIRE April 26, 2021 Nascent Biotech, Inc. OTCQB:NBIO Nascent Biotech, Nascent, or the Company, a clinical-stage biotechnology company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce that It has paid off and eliminated a major convertible debt note, pre-emptively preventing a dilutive conversion. The note, which was held by JSJ Investments, LLC JSJ, represented over 186k in debt carried pre-conversion on the Companys balance sheet. 